235 related articles for article (PubMed ID: 30221940)
1. Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.
Huddle BC; Grimley E; Buchman CD; Chtcherbinine M; Debnath B; Mehta P; Yang K; Morgan CA; Li S; Felton J; Sun D; Mehta G; Neamati N; Buckanovich RJ; Hurley TD; Larsen SD
J Med Chem; 2018 Oct; 61(19):8754-8773. PubMed ID: 30221940
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells.
Jiménez R; Pequerul R; Amor A; Lorenzo J; Metwally K; Avilés FX; Parés X; Farrés J
Chem Biol Interact; 2019 Jun; 306():123-130. PubMed ID: 30958995
[TBL] [Abstract][Full Text] [Related]
3. ALDH1A inhibition sensitizes colon cancer cells to chemotherapy.
Kozovska Z; Patsalias A; Bajzik V; Durinikova E; Demkova L; Jargasova S; Smolkova B; Plava J; Kucerova L; Matuskova M
BMC Cancer; 2018 Jun; 18(1):656. PubMed ID: 29902974
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
5. Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy.
Huddle BC; Grimley E; Chtcherbinine M; Buchman CD; Takahashi C; Debnath B; McGonigal SC; Mao S; Li S; Felton J; Pan S; Wen B; Sun D; Neamati N; Buckanovich RJ; Hurley TD; Larsen SD
Eur J Med Chem; 2021 Feb; 211():113060. PubMed ID: 33341649
[TBL] [Abstract][Full Text] [Related]
6. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
7. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Chefetz I; Grimley E; Yang K; Hong L; Vinogradova EV; Suciu R; Kovalenko I; Karnak D; Morgan CA; Chtcherbinine M; Buchman C; Huddle B; Barraza S; Morgan M; Bernstein KA; Yoon E; Lombard DB; Bild A; Mehta G; Romero I; Chiang CY; Landen C; Cravatt B; Hurley TD; Larsen SD; Buckanovich RJ
Cell Rep; 2019 Mar; 26(11):3061-3075.e6. PubMed ID: 30865894
[TBL] [Abstract][Full Text] [Related]
8. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.
Hirst J; Pathak HB; Hyter S; Pessetto ZY; Ly T; Graw S; Koestler DC; Krieg AJ; Roby KF; Godwin AK
Cancer Res; 2018 Aug; 78(15):4370-4385. PubMed ID: 29891506
[TBL] [Abstract][Full Text] [Related]
9. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
10. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
11. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
[TBL] [Abstract][Full Text] [Related]
12. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Luo Y; Dallaglio K; Chen Y; Robinson WA; Robinson SE; McCarter MD; Wang J; Gonzalez R; Thompson DC; Norris DA; Roop DR; Vasiliou V; Fujita M
Stem Cells; 2012 Oct; 30(10):2100-13. PubMed ID: 22887839
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M
Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
15. Development of substituted benzimidazoles as inhibitors of human aldehyde dehydrogenase 1A isoenzymes.
Takahashi C; Chtcherbinine M; Huddle BC; Wilson MW; Emmel T; Hohlman RM; McGonigal S; Buckanovich RJ; Larsen SD; Hurley TD
Chem Biol Interact; 2024 Mar; 391():110910. PubMed ID: 38364885
[TBL] [Abstract][Full Text] [Related]
16. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
[TBL] [Abstract][Full Text] [Related]
17. Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy.
Sharrow AC; Perkins B; Collector MI; Yu W; Simons BW; Jones RJ
Gynecol Oncol; 2016 Aug; 142(2):341-8. PubMed ID: 27017984
[TBL] [Abstract][Full Text] [Related]
18. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
Yokoyama Y; Zhu H; Lee JH; Kossenkov AV; Wu SY; Wickramasinghe JM; Yin X; Palozola KC; Gardini A; Showe LC; Zaret KS; Liu Q; Speicher D; Conejo-Garcia JR; Bradner JE; Zhang Z; Sood AK; Ordog T; Bitler BG; Zhang R
Cancer Res; 2016 Nov; 76(21):6320-6330. PubMed ID: 27803105
[TBL] [Abstract][Full Text] [Related]
19. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.
Moreb JS; Ucar D; Han S; Amory JK; Goldstein AS; Ostmark B; Chang LJ
Chem Biol Interact; 2012 Jan; 195(1):52-60. PubMed ID: 22079344
[TBL] [Abstract][Full Text] [Related]
20. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
